By: SUE32073
21 Apr 2004, 07:50 AM EDT
Msg. 148136 of 148332
(This msg. is a reply to 148129 by rickv.)
Jump to msg. #  
ricky.....FYI

"In connection with the employment of its Chief Financial Officer, the Company granted Alan Gallantar options to purchase an aggregate of 4,547,880 shares of the Company's common stock. Such options have a term of ten years commencing October 1, 1999 through September 30, 2009
and have an exercise price of $0.24255 per share. These options are fully vested."

By: 4titudinous
21 Apr 2004, 08:11 AM EDT
Msg. 148138 of 148332
Jump to msg. #  
No AVR118, yet. Weizmann re: benefit of garlic:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15056375

By: DIAMONDring
21 Apr 2004, 08:22 AM EDT
Msg. 148139 of 148332
Jump to msg. #  
sue he wont sell his options he will hold them forever waiting and knowing the true potential of advr like all us idiot longs have done i bet he buys more (not)!!!! i just hope as he walks out the door hes not laughing if you no what i mean.
By: DIAMONDring
21 Apr 2004, 08:32 AM EDT
Msg. 148141 of 148333
Jump to msg. #  
i remember many here saying WAIT TILL
we get dr h.
we get results for hpv
we get results for topical
we get pink eye results
we get china and other patents
we get rid of dr h.
we get exposure at conferences
we get argentina test results
we get isreal test results
we get financing
we get the new boss
we get rid of overpaid galanter
we get that abstract exposure
we got .117 after all that the new boss must be very impressive i bet big pharms are upset they didnt get her.
theres no bs in this post and yes ill buy more it just seems strange that we have (a miracle drug) and after 20 years nobody in the world thinks so but us at rb.


By: SUE32073
21 Apr 2004, 08:44 AM EDT
Msg. 148142 of 148333
(This msg. is a reply to 148138 by 4titudinous.)
Jump to msg. #  
"On July 8, 2002, the Company extended an agreement with the Weizmann Institute of Science and Yeda its developmental arm in Israel, to conduct research on the effects of AVR118 on the immune system, especially on T lymphocytes. In addition, scientists will explore the effects of AVR118 in animal models. Under its provisions the study period is extended for another twelve months to July 7, 2003. Total costs incurred in connection with this research are expected to be $138,000. Since inception, through December 31, 2003, the Company expensed $120,000 and paid $90,000 in connection with this agreement. Final payment has not been made pending receipt, review and approval of the final report."

Since we have not heard anything published yet from the Weizmann studies -- IS IT POSSIBLE, some sort of Abstract concerning "T lymphocytes" will be presented by the company at the ASCO conference? Perhaps, the company is going to make that final payment to Weizmann? Just some thoughts!!!
By: Ourobouros
21 Apr 2004, 09:35 AM EDT
Msg. 148149 of 148333
(This msg. is a reply to 148146 by tellslikeitis.)
Jump to msg. #  
Larry Pomerantz::

http://www.edgar-online.com/brand/yahoo/people/?last=POMERANTZ&first=LARRY&ftype=ALL

 
 
  click to retrieve filingclick to retrieve filing
last name
 first name
date date company name
POMERANTZ
 LARRY
1/29/04 S-1
Initial Registration Statement
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
12/23/03 10-Q/A
Amended Quarterly Report
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
12/19/03 10-Q/A
Amended Quarterly Report
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
12/19/03 S-1/A
Amended Initial Registration Statement
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
11/18/03 S-1/A
Amended Initial Registration Statement
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
9/19/03 S-1/A
Amended Initial Registration Statement
ADVANCED VIRAL RESEARCH CORP
POMERANTZ
 LARRY
1/13/99 S-1
Initial Registration Statement
ADVANCED VIRAL RESEARCH CORP
 
Plain Text HTML

 
Try EDGAR Online Premium - free for two weeks! - click here.

 

By: lovingitall0
21 Apr 2004, 10:42 AM EDT
Msg. 148166 of 148337
Jump to msg. #  
HIV in China

WHO Director General Calls for Increased Attention to HIV in China

Apr 21, 2004

World Health Organization Director-General Jong-Wook Lee on Tuesday during a lecture at the Beijing Union Medical College in China called on the Chinese government to pay more attention to tuberculosis and HIV/AIDS in the country, Xinhuanet/China View reports. During his two-day visit -- his first official visit to the country since assuming his position in July 2003 -- Lee also met with Chinese leaders and health officials (Xinhuanet/China View, 4/20).

The Chinese government estimates that there are 840,000 HIV-positive people in the country and that 80,000 people have AIDS; however, some experts believe that those figures are underestimates. The United Nations estimates that there are at least one million HIV-positive people in China and that the number could grow to 20 million people by 2010
(Kaiser Daily HIV/AIDS Report, 4/15).

Lee also was scheduled to meet with Chinese Premier Wen Jiabao to discuss China's role in WHO's 3 by 5 Initiative, which aims to provide antiretroviral drugs to three million HIV-positive people worldwide by 2005 (Agence France-Presse, 4/19). About 60,000 to 70,000 of the people treated in the program would be in China, according to Kyodo News (Kyodo News, 4/19).

By: tellslikeitis
21 Apr 2004, 10:48 AM EDT
Msg. 148167 of 148337
(This msg. is a reply to 148163 by anna_mny.)
Jump to msg. #  
anna mny : Alan, the ex-CFO had loaned the company personal funds at a time when it was almost bankrupt, to help keep operations going a month or two. This had been recorded in an SEC filing.
By: Ourobouros
21 Apr 2004, 10:56 AM EDT
Msg. 148169 of 148339
(This msg. is a reply to 148168 by nvphyl.)
Jump to msg. #  
"Answer this question. Does "IT work?"

------------------------

Unfortunately ADVR has never been able to get ANY bona-fide testing trials to completion to answer your very basic question.
By: BarryAllen
21 Apr 2004, 11:01 AM EDT
Msg. 148170 of 148339
(This msg. is a reply to 148167 by tellslikeitis.)
Jump to msg. #  
At least be honest Tele.... Gallantar loaned the company some funds, short term with interest, so the company could hurry up and pay Bregman and Friedland their severance pay!

The CEO & CFO couldn't wait to get rid of the founders ASAP. Bregman was actually evicted by Gallantar personally!

That was the beginning of the "death spiral" of ADVR that got us in the position we are today created by all the "quality investor" financing Hirschman and Gallantar brought to the table since!

Gallantar did very well with his salary and options in the realm of working for a tiny OTCBB startup with no revenues.

Even EVEN will agree with that statement!


- - - - -
View Replies

By: rarboston
21 Apr 2004, 11:29 AM EDT
Msg. 148172 of 148339
(This msg. is a reply to 148163 by anna_mny.)
Jump to msg. #  
Anna -- No, he has been working without a contract for 18 months and is part of the old regime..... It was time for his departure...no big whoop.

Unless something dramatic turns up (like filing false SEC docs), his departure is no big deal IMO.
By: anna_mny
21 Apr 2004, 11:36 AM EDT
Msg. 148176 of 148339
(This msg. is a reply to 148167 by tellslikeitis.)
Jump to msg. #  
tellslikeitis,

Thank You. I take it the man has fallen ill or someone
close has on the one hand but if he indeed loaned personal
funds to keep Advanced Viral aflot, why the lack of celebratory accolades in the press release ?

Just an observation.

I think there is a lot of risk with Advanced Viral
and potential large upside.

Seems like the company as well as the board from what
I read has been through very rough times.

Has it been considered that this Mr K the Klown is an
ex employee ?

I have seen people who were let go, unleash such havoc.
Its unfortunate but better on a forum board than at a company location.

Thank You

anna
By: Ourobouros
21 Apr 2004, 11:38 AM EDT
Msg. 148177 of 148339
(This msg. is a reply to 148173 by yanks04.)
Jump to msg. #  
It was my understanding that there were multiple occasions when investors wanted in and SZH vetoed the arrangement for various reasons - one of which was that there was a personality clash.

Now why would someone heading up a company in dire financial straits and struggling to stay afloat abandon an offer because of discrepancies of personalities??

Only at ADVR headquarters - and one of the reasons the company is trading so low now.


By: yosselone
21 Apr 2004, 11:45 AM EDT
Msg. 148180 of 148339
Jump to msg. #  
2/25/04. ADVR Granted a United States Patent for the Treatment of AIDS


25 February 2004, 08:14am ET

YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) today announced that it was issued a United States patent (No. 6,696,422) for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs.

The Centers for Disease Control and Prevention (CDC) estimates that 850,000 to 950,000 United States residents are living with HIV infection, one-quarter of whom are unaware of their infection. Over 40,000 new patients are diagnosed with HIV infections each year in the United States -- about 70 percent among men and 30 percent among women. Of these newly infected people, half are younger than 25 years of age.

"The issuance of this patent allows us to increase our intellectual property protection in an important therapeutic area," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "We previously announced that China granted the Company a similar patent for AVR118 in the treatment of HIV infections."

ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

Mentioned Last Change
ADVR 0.11 0.01dollars or (8.33%)
For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (previously known as Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802


SOURCE Advanced Viral Research Corp.
-0- 02/25/2004
/CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners, for
Advanced Viral Research Corp., +1-508-222-4802/
/Company News On-Call:

http://www.prnewswire.com/comp/903002.html/

/Web site:

http://www.adviral.com/

(ADVR)

CO: Advanced Viral Research Corp.
ST: New York
IN: MTC HEA BIO OTC
SU:

MT
-- NYW083 --
7370 02/25/2004 08:14 EST

http://www.prnewswire.com

E-mail this story Print this story
Advanced Viral Resrh (BB) News
Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
20 April 2004, 07:20am ET, PR Newswire

ADVR Appoints Dr. Carol Epstein as Acting Medical Director
8 April 2004, 07:30am ET, PR Newswire

ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
19 March 2004, 07:30am ET, PR Newswire

More ADVR News



By: yosselone
21 Apr 2004, 11:50 AM EDT
Msg. 148181 of 148339
Jump to msg. #  
3/19/04. ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
19 March 2004, 07:30am ET

YONKERS, N.Y., March 19 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that an abstract on AVR118 has been selected for presentation at The American Society of Clinical Oncology's (ASCO) 40th Annual Meeting to be held in New Orleans, LA, June 5-8, 2004. The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.

The ASCO Annual Meeting is the premiere educational event in the clinical oncology community. The meeting is targeted to U.S. and international physicians, academicians, and clinical researchers, as well as oncology fellows, nurses, social workers, physician assistants, and other healthcare professionals involved in multidisciplinary clinical cancer care. The 2003 Meeting in Chicago attracted 26,400 attendees from all over the world.

Mentioned Last Change
ADVR 0.11 0.01dollars or (8.33%)
For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802


SOURCE Advanced Viral Research Corp.
-0- 03/19/2004
/CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners,
+1-508-222-4802, for Advanced Viral Research Corp./
/Company News On-Call:

http://www.prnewswire.com/comp/903002.html

/
/Web site:

http://www.adviral.com

/
(ADVR)

CO: Advanced Viral Research Corp.; American Society of Clinical Oncology
ST: New York
IN: BIO HEA MTC OTC
SU: TDS

GS
-- NYF013 --
3666 03/19/2004 07:30 EST

http://www.prnewswire.com

E-mail this story Print this story
Advanced Viral Resrh (BB) News
Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
20 April 2004, 07:20am ET, PR Newswire

ADVR Appoints Dr. Carol Epstein as Acting Medical Director
8 April 2004, 07:30am ET, PR Newswire

ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
19 March 2004, 07:30am ET, PR Newswire

More ADVR News


- - - - -
By: billblueyz
21 Apr 2004, 11:50 AM EDT
Msg. 148182 of 148339
Jump to msg. #  
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.
WELL THE ABOVE IS TRUE EXCEPT FOR THE MOST IMPORTANT POINT, THE BRINGING TO MARKET POINT, AND IT SEEMS THEY CAN'T EVEN FINISH THE RESEARCH PART. JMHO

By: yosselone
21 Apr 2004, 11:51 AM EDT
Msg. 148183 of 148339
Jump to msg. #  
4/8/04. ADVR Appoints Dr. Carol Epstein as Acting Medical Director


8 April 2004, 07:30am ET

YONKERS, N.Y., April 8 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that Carol Epstein, MD has been appointed Acting Medical Director for the Company. Dr. Epstein is the co-founder of MediVector, Inc., a biopharmaceutical consulting firm with proprietary technology that can enable companies to cut the time and cost of drug development.

"I am extremely pleased that Dr. Epstein has joined our team. Carol is known for her creative and strategic thinking," said Elma S. Hawkins, PhD, MBA, President and CEO of Advanced Viral Research Corp. "With her wealth of knowledge and expertise in clinical research and drug development, Carol is uniquely qualified to assist us in translating AVR118 into commercial realization. This marks the first time we have had someone with Dr. Epstein's level of expertise in clinical development at ADVR and demonstrates our commitment and focus in this area."

Dr. Epstein started her career in the pharmaceutical industry in 1983 with Ayerst, a division of American Home Products. She then joined Immunex where she built the clinical group and was responsible for the successful clinical strategy that led to the approval of GM-CSF. Dr. Epstein later became Chief Medical Officer of Immunogen, and then co-founded BioLogics Services, Inc, a biopharmaceutical consulting firm. She has had extensive experience in oncology, immunology and autoimmune diseases, wound healing, cardiology, endocrinology and metabolism, and transplantation. Dr. Epstein graduated from MIT and Yale University School of Medicine.

"I look forward to working with ADVR in developing and executing a comprehensive strategic plan for the clinical development of this very interesting and promising product," said Dr. Epstein.

Mentioned Last Change
ADVR 0.113 0.007dollars or (5.83%)
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R), represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com .

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact: Ronnie Welch or Kelly Cinelli
CWR & Partners
508/222-4802


SOURCE Advanced Viral Research Corp.
-0- 04/08/2004
/CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners,
+1-508-222-4802, for Advanced Viral Research Corp./
/Company News On-Call:

http://www.prnewswire.com/comp/903002.html

/
/Web site:

http://www.adviral.com

/
(ADVR)

CO: Advanced Viral Research Corp.
ST: New York
IN: MTC BIO HEA OTC
SU: PER

WR
-- NYTH011 --
6818 04/08/2004 07:30 EDT

http://www.prnewswire.com

E-mail this story Print this story
Advanced Viral Resrh (BB) News
Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
20 April 2004, 07:20am ET, PR Newswire

ADVR Appoints Dr. Carol Epstein as Acting Medical Director
8 April 2004, 07:30am ET, PR Newswire

ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
19 March 2004, 07:30am ET, PR Newswire

More ADVR News


By: yosselone
21 Apr 2004, 11:52 AM EDT
Msg. 148186 of 148339
Jump to msg. #  
4/20/04. Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer


20 April 2004, 07:20am ET

YONKERS, N.Y., April 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that Mr. Alan Gallantar has resigned as Chief Financial Officer and Treasurer effective April 19th, 2004. Mr. Gallantar informed the Company that he is leaving ADVR to attend to a personal matter.

Mr. Martin Bookman, who has been with ADVR as Assistant Controller since March of 2001, has been appointed Acting Chief Financial Officer.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R), represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

Mentioned Last Change
ADVR 0.113 0.007dollars or (5.83%)
For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com .

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802


SOURCE Advanced Viral Research Corp.
-0- 04/20/2004
/CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners,
+1-508-222-4802, for Advanced Viral Research Corp. /
/Company News On-Call:

http://www.prnewswire.com/comp/903002.html

/
/Web site:

http://www.adviral.com

/
(ADVR)

CO: Advanced Viral Research Corp.; ADVR
ST: New York
IN: HEA MTC BIO OTC
SU: PER

KB
-- NYTU080 --
6779 04/20/2004 07:20 EDT

http://www.prnewswire.com

E-mail this story Print this story
Advanced Viral Resrh (BB) News
Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
20 April 2004, 07:20am ET, PR Newswire

ADVR Appoints Dr. Carol Epstein as Acting Medical Director
8 April 2004, 07:30am ET, PR Newswire

ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
19 March 2004, 07:30am ET, PR Newswire

More ADVR News

By: DIAMONDring
21 Apr 2004, 01:03 PM EDT
Msg. 148208 of 148368
Jump to msg. #  
bring back (im gonna puke) bregmenn

Advertisements
By: BarryAllen
21 Apr 2004, 02:48 PM EDT
Msg. 148248 of 148368
Jump to msg. #  
anna... here is some history on the ex-CFO. Ask anyone here if he met his goals, especially 2-6. But he did loan some big bucks to get rid of the founders, Breg & Fried!

EXHIBIT A-1
-----------

Corporate Performance Goals
---------------------------


The corporate objectives, the attainment of which 50% of the
discretionary bonus payable to the Employee will depend, include the following:

1. Approval of one or more IND's by the United States Food and Drug
Administration;

2. Increased values for shareholders reflected by long term stock price
appreciation;

3. Attainment of listing on NASDAQ SmallCap Market and, subsequently, on
the NASDAQ National Market;

4. The execution of material license agreements with attendant royalty
streams payable to the Corporation;

5. Successful completion of corporate finance transactions resulting in
the infusion of equity, quasi equity and/or long term debt into the
Corporation (not including so called "death spiral" transactions);

6. Joint venture transactions with major pharmaceutical companies;




17





EXHIBIT A-2
-----------

Individual Performance Goals1
-----------------------------

The individual objectives, the attainment of which 50% of the
discretionary bonus payable to the Employee will depend, include the following:

1. Establish and maintain policies for effective investor communications;

2. Establish and maintain financial controls, reporting systems and
accounting policies and provide timely and accurate operating
information to management and regulatory agencies;

3. Move the accounting, legal and financial reporting functions to New
York headquarters;

4. Prepare budgets for the Company;

5. Establish and maintain an approval process for growth and development
plans;

6. Analyze results of operations versus budget and prior year results of
operations;

7. Make recommendations to the CEO and Board of Directors with respect to
operating efficiencies;

8. Develop and supervise staff;

9. Develop and maintain a corporate culture and mission statement;

10. Develop and maintain investor communications procedures;

11. Develop and maintain employee benefit plans, including a 401(k) plan;

12. Discuss, develop and maintain a business plan strategy for the Company;

13. Develop and maintain corporate governance policies to expand the
breadth of the Board of Directors and Advisory Boards;

14. Develop and maintain risk management policies for the Company;

15. Develop intangible property policies for the Company;

16. Maintain an ongoing relationship between the Company and NASDAQ and
market makers;

17. Develop a strategy to move the Company from OTC Bulletin Board to
NASDAQ SmallCap listing.



 

By: BarryAllen
21 Apr 2004, 03:00 PM EDT
Msg. 148259 of 148370
(This msg. is a reply to 148241 by yanks04.)
Jump to msg. #  
yanks.....MM's are holding ADVR until they accumulate enough shares for the BIG run on significant news. The MM's are very smart. They know that no more "quality investors" are coming since the Dickie boys ponied up $12MM. They have to accumulate and/or cover because next time ADVR runs, it may not come back. The PPS might drift down to .08 but I don't care, I've been here for almost 10 years and have lot's of patience. Life goes on and time goes by. Many opportunities were here to make money on ups and downs and there will be more, especially a BIG one. The best way to handle ADVR is not to microwatch the PPS but to diversify on other stocks until the BIG day arrives and it WILL come!
By: BarryAllen
21 Apr 2004, 03:36 PM EDT
Msg. 148279 of 148372
(This msg. is a reply to 148187 by anna_mny.)
Jump to msg. #  
anna.....Gallantar loaned $200k to the company so they could dump Breg and Fried ASAP.

He got his money back when Harborview(Larry Pomerantz-who Telit trashed earlier) invested some more of his and his group's money in ADVR.

Makes you wonder how a CFO who had cash, never invested a single penny into the company that paid him handsomely for 3 years + 18 months? Not to mention our illustrious ex-CEO, Dr. H!

The Agreements, attached hereto as Exhibits 10.1, 10.2 and 10.3,
provide for, among other things, the payment of $150,000 in one lump sum to each
of Messrs. Bregman and Friedland, and the payment of $2,500 to Mr. Silver, in
consideration for their resignation as directors and/or officers of the
Registrant and its subsidiary.

In connection with the Agreements, the Registrant obtained a loan in
the amount of $200,000 from its Chief Financial Officer, Alan Gallantar, as
evidenced by a Demand Promissory Note made by the Registrant in favor of Mr.
Gallantar attached hereto as Exhibit 10.4 (the "Note"). Pursuant to the terms of
the Note, the Registrant was obligated to repay the promissory note upon the
receipt by the Registrant of proceeds upon the consummation of new financing.
The Note was satisfied by the Registrant upon the receipt by the Registrant of
proceeds in connection with a Securities Purchase Agreement dated December 17,
2001 between the Registrant and Harbor View Group, Inc.





(Voluntary Disclosure: Position- Long)

- - - - -
By: Ourobouros
21 Apr 2004, 04:09 PM EDT
Msg. 148312 of 148372
(This msg. is a reply to 148306 by BarryAllen.)
Jump to msg. #  
"MM's walking it down on the BS CFO news release."

Or maybe folks are simply tired of ADVR's never-ending series of failures, and are just selling??

Why is it always the MMs fault that a company's stock has a declining PPS?

By: BarryAllen
21 Apr 2004, 04:46 PM EDT
Msg. 148329 of 148372
(This msg. is a reply to 148312 by Ourobouros.)
Jump to msg. #  
Bernie, no one is blaming the MM's...they have a job to do.....get as much stock as they can to provide liquidity to the market.

It is no secret when a company puts out what is perceived as bad news the MM's start pulling the Bids as some selling begins. It usually ends in a "hammer" bottom and the price quickly bounces back.

The drop has begun as you can see on today's daily chart and will probably bounce around .08 which would be a tremendous buying opportunity.....time to put those HLSH profits back to work! LOL!

By: lovingitall0
21 Apr 2004, 04:58 PM EDT
Msg. 148332 of 148372
(This msg. is a reply to 148329 by BarryAllen.)
Jump to msg. #  
"The drop has begun as you can see on today's daily chart and will probably bounce around .08 which would be a tremendous buying opportunity.....time to put those HLSH profits back to work! LOL!

Seriously, ADVR has never been in better shape. They got the MONEY. They now have the management. And.....they have the DRUG!!!"
---------------------
You got it Babe!

LIA
By: SUE32073
21 Apr 2004, 07:40 PM EDT
Msg. 148373 of 148399
(This msg. is a reply to 148372 by anna_mny.)
Jump to msg. #  
Hi Anna,

Not sure why the drop....possibly because there is nothing new to report in a positive venue. I don't think the loss of ADVR's CFO is that big of a deal (I really don't)...heck, I don't even think the stock dropped at all when Dr. Hirschman resigned as CEO and Director. It's possible there are "forces" out there playing on this aspect, but I don't think as the MM's do, so I don't know for sure.

BTW: I am a bit jealous of your entry price. I came in at $.75 and bought again at $.50 (those were the good old days when a chipmunk could pump ADVR and a lot of us "believed"). ADVR keeps spinning its wheels in different directions, and I've grown accustomed to its face. I'm about ready for an ADVR facelift!!

Cheers!
Sue
By: BarryAllen
21 Apr 2004, 07:50 PM EDT
Msg. 148374 of 148399
(This msg. is a reply to 148344 by sardti.)
Jump to msg. #  
Excellent post....thanks for pointing this out.

The up side of AG leaving is a reduction in payroll. He was grossly overpaid for ADVR's position in the bio market . Look at the money we have saved. When SH's contract is up there should be some further savings.

(Voluntary Disclosure: Position- Long)
By: anna_mny
21 Apr 2004, 07:50 PM EDT
Msg. 148375 of 148399
(This msg. is a reply to 148373 by SUE32073.)
Jump to msg. #  
SUE, The past CEO made over 500K !
The new CEO much less. Advanced Viral should show a profit
just on that lol
Well if the company cut some corners and move the drug
along, we both will be happy no matter where we bought.
We do not hold a lot of shares. Admire your patience !

have a good evening
anna
By: SUE32073
21 Apr 2004, 08:16 PM EDT
Msg. 148376 of 148399
(This msg. is a reply to 148375 by anna_mny.)
Jump to msg. #  
LOL...Anna, believe it or not, the company is STILL PAYING the former CEO THE SAME SALARY plus perks (even after his resignation - his title is now Chief Scientist, that is until this December) AND is ALSO paying THE NEW CEO HER SALARY plus 40 million shares in options. You really NEED to read the last SEC report (10-K). Read the employment contracts. The company really DOES take care of its own!!!....LOL. Even though the lowly shareholders are "declared" to be the backbone of the company.

Good night; may ADVR have a better day tomorrow!
By: mbengineer
21 Apr 2004, 09:31 PM EDT
Msg. 148377 of 148399
Jump to msg. #  
Ana The Co has finally put itself lin a postion to move fofward wth the new CEO and acting medical director. While the CEO is still familurizing herself with all hat went on for the last 15 years so that she may be able to make the info usefull, the Co must still proceed sswith these qualified persons. In the long run, the stockolders will gain from this short period.
By: kevtod
21 Apr 2004, 10:40 PM EDT
Msg. 148383 of 148400
Jump to msg. #  
"TB Case Found at Yonkers High; 100 to Be Tested"

Associated Press (04.20.04)

Westchester County Health Department officials are
suggesting skin tests for about 100 students and staff members at Yonkers High School after a person there was diagnosed with TB. Those who shared a classroom with the infected person or had other significant contact should undergo the tests, which will be offered at the school or can be taken in a doctor's office, said Health Commissioner Joshua Lipsman. The county usually sees 60-70 TB cases annually.
*****************************************************